← All trials
NCT06514963
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2024
- Primary completion
- Oct 20, 2024
- Completion date
- Nov 10, 2024
- First posted
- Jul 23, 2024
- Last posted
- Jul 26, 2024
- Enrollment
- 74
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.